• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Biotherapeutics Discovery Biotherapeutics Discovery

Biotherapeutics Discovery

High-quality large molecule discovery services supported by cutting-edge facilities with a focus on scientific innovation.

Aurigene Pharmaceutical services is rapidly positioning itself to provide high-quality and high-value large molecule discovery services in traditional and advanced drug modalities. We have capabilities for ‘Target to Preclinical Proof-of-Concept’. We provide wide range of large molecule discovery services from our R and D center in Hyderabad. Our R and D site is US FDA inspected. Our infrastructure is well-equipped with :

BSLII compliant labs Spectrophotometer Flow cytometer Mass Spectrometer (Agilent 6545 Q-TOF))
Analytical HPLC FPLCs (AKTA) SPR-BIAcore T200 Automated western (Simple JESS)
Automated liquid handler (Bravo) Lab scale LNP formulation set-up for mRNA Real-Time PCR (96 and 384 well plate) Gel documentation systems
Benchtop fermenter for yeast and E. coli Static incubators and shakers Multimode plate readers (Victor & Envision) Tape station
Preparatory ultracentrifuge Cell disruptor/French press Independent cell culture suites with microscope, liquid nitrogen storage, biosafety cabinets, static and shaker CO 2 incubators, Centrifuges.

We adhere to strong data integrity and traceability framework which is embedded in our SOPs and IT systems. We have daily automatic backups for all generated data.

Speak to our Experts
 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack